cyrilzakka/clinical-trials huggingface dataset:
Median Effective Dose of Esketamine Pretreatment to Prevent Sufentanil-induced Cough

Sufentanil has the advantages of fast onset time, strong analgesic function and cardiovascular stability, and is widely used during general anesthesia induction. However, sufentanil can cause cough during induction of general anesthesia. Different studies have reported that the incidence of sufentanil-induced cough ( SIC ) during anesthesia is 16-42 %. This pathological condition may lead to damage to the central nervous system, increase the risk of reflux and aspiration, increase intracranial pressure and intraocular pressure, and endanger patients with cerebral aneurysms and ocular trauma. Therefore, at the moment of advocating comfortable anesthesia medical services, sufentanil-induced cough response is a problem that clinical anesthesiologists need to focus on and urgently solve. It has been reported that ketamine can reduce the incidence of cough caused by opioids. Esketamine is a pure dextro-enantiomer of ketamine and an NMDA antagonist with potent analgesic and bronchodilator effects. In this study, Dixon sequential method was used to study the median effective dose ( ED50 ) of intravenous esketamine pretreatment to prevent sufentanil-induced cough, and to explore the effect of age on ED50. To provide reference for clinical rational selection of esketamine dose.


Eligibility Criteria:
Inclusion Criteria:

ASA I-II patients aged 18-59 years undergoing elective surgery under general anesthesia

Exclusion Criteria:

1. Preoperative intracranial pressure;
2. intra-abdominal pressure or intraocular pressure increased ;
3. have a history of cardiovascular and cerebrovascular diseases ;
4. have a history of asthma ;
5. have a history of chronic cough ;
6. have a history of smoking ;
7. there was a history of upper respiratory tract infection 2 weeks before operation;
8. Patients received opioid therapy 2 weeks before surgery.;
9. Patients who received angiotensin converting enzyme inhibitors, bronchodilators or steroids 2 weeks before surgery ;
10. abnormal liver and kidney function ; weight exceeded 20 % of the ideal weight ( male height - 100, female height - 105 ).
Tirbanibulin for Pediatric Warts

Warts are common, benign skin lesions caused by the human papillomavirus (HPV). Treatment is challenging, particularly in the pediatric population, where standard modalities such as cryotherapy and intralesional immunotherapy are poorly tolerated. Existing topical treatments, such as imiquimod and 5-fluorouracil, have low efficacy and require prolonged use. Case reports suggest tirbanibulin ointment may provide an effective and well-tolerated alternative for pediatric warts. This study will evaluate the efficacy and safety of tirbanibulin ointment in treating pediatric hand warts.


Eligibility Criteria:
Inclusion Criteria:

1. Age 8-18
2. Subject and their legally authorized representative must be able to understand and be willing to adhere to all protocol requirements and voluntarily sign and date informed consent and assent for minors.
3. Subject is judged to be in good health as determined by the Principal Investigator, based upon the results of the screening assessments and medical history.
4. Diagnosis of warts on the hands
5. Wart count on the hands and 3-10

Exclusion Criteria:

1. Wart duration \>2 years.
2. More than 10 warts in non-hand areas.
3. Total wart surface area on the hands bigger than 100 cm2
4. Prior treatment failure with the following modalities:

1. intralesional immunotherapy 2. intralesional bleomycin, 5-fluorouracil, methotrexate 3. intralesional cidofovir 5. Any over the counter, prescription topical, or in-office procedural wart treatment within 6 weeks of baseline (Day 1) 6. Known immuno-suppressed state due to disease or medication, medical treatment o 7. Known allergy to any component of the IP 8. Any conditions that, in the Principal Investigator's opinion, may interfere with the course of the study
Exploring the Relationships Among Hospital's Corporate Social Responsibility, Job Attitudes and Job Performance

In recent years, many hospitals have progressively perceived the importance of corporate social responsibility (CSR). More and more hospital superintendents thus have realized that they should have a CSR strategy to deal with various stakeholders. Hospital, as a health care sector, is a labor-intensive industry. The management of hospitals should view its employees as salient stakeholders as well as a sort of precious asset by which hospital can possess a unique competition advantage in the operation. It is therefore important for superintendent to understand an employee's perspective on CSR and its impact on employees' work attitudes and organizational performance.

Based on the stakeholder theory and social identity theory, this study attempts to employ a survey approach to understand the superintendents and employees' perceptions of CSR, and to explore the effects of CSR on organizational commitment of employees and organizational performance. The samples are taken from the senior managers (such as the superintendent and vice superintendent) and employees in the hospitals of which the number of beds are more than 200. The structural equation modeling (SEM) is applied to confirm the research framework and to test the hypotheses. The results will provide a reference for the management and regulators of hospitals to set up the CSR policies, and contribute to senior managers on the CSR strategy and human resource development with regard to hospitals.

Eligibility Criteria:
Inclusion Criteria:

* senior managers (such as the superintendent and vice superintendent) and employees in the hospitals

Exclusion Criteria:

* none
Effects of Dietary Omega-3 Fatty Acids on Reproductive Hormones in Obese Women

The United States has the highest prevalence of obesity among all countries surveyed in 2012 by the Organization for Economic Cooperation and Development. Maternal obesity is linked with anovulation, menstrual cycle abnormalities, subfertility, fetal loss, obstetrical complications and congenital anomalies. Changes in reproductive hormones and diminished oocyte quality have also been demonstrated. A gap of knowledge exists as the mechanisms underlying these harmful effects are poorly understood and no specific treatments exist.

This proposal will test the hypothesis that dietary omega-3 fatty acids (FA) will improve the output of hypothalamicpituitary- ovarian axis in obese women. The investigators will perform paired assessments before and after supplementation in 10 obese and 10 normal weight women. To test the pituitary and hypothalamic output, the investigators will examine the luteinizing hormone (LH) and follicle-stimulating hormone (FSH) responsiveness during frequent blood sampling. To test the corpus luteum function, the investigators will examine urinary reproductive hormones (E1c, estrone conjugates, and pregnanediol glucuronide (Pdg)) over an entire menstrual cycle. The investigators ultimate goal is to collect preliminary data for an adequately powered randomized control trial.


Eligibility Criteria:
Inclusion Criteria:

1. Age 18-42 at study entry
2. Regular menstrual cycles every 25-40 days
3. BMI at least 30 kg/m2 (obese) or between 18.5 and 25 kg/m2 (normal)
4. Good general health
5. Prolactin and thyroid-stimulating hormone (TSH) within normal laboratory ranges at screening, baseline hemoglobin \>11 gm/dl.

Exclusion Criteria:

1. Diagnosis of polycystic ovary syndrome (by ultrasound or hyperandrogenic symptoms)
2. Fish or seafood allergy or hypersensitivity (e.g., anaphylactic reaction) to omega-3-acid ethyl esters or any component of the formulation
3. Coagulopathy or receiving therapeutic anticoagulation (due to potential for interaction with omega-3 FA)
4. History of chronic disease affecting hormone production, metabolism or clearance (including diabetes mellitus)
5. Abnormal renal or liver function at screening
6. Current use of thiazolidinediones or metformin (known to interact with reproductive hormones)
7. Use of hormones affecting hypothalamic output (HPO) axis (such as hormonal contraceptives) within three months of entry
8. Strenuous exercise (\>4 hours of intense physical activity per week)
9. Pregnancy
10. Breast-feeding
11. Current active attempts to conceive
12. History of significant recent weight loss or gain
Effectiveness of Selegiline in Treating Marijuana Dependent Individuals - 1

During the past 15 years, the demand for treatment for marijuana-related problems in the United States has increased nearly twofold. Selegiline is a medication currently used to treat nicotine dependence. The purpose of this study is to evaluate whether selegiline may be useful in treating individuals with marijuana dependence.

Behavioral therapy paired with drug therapy might be a more effective treatment approach to marijuana dependence than behavioral therapy alone. Selegiline is a monoamine oxidase-B inhibitor. It increases dopamine activity in parts of the brain that are involved in dependence on addictive drugs such as nicotine, cocaine, and marijuana. Selegiline has been effective in treating nicotine dependence, but has not yet been studied in treating marijuana dependent individuals. The purpose of this study is to evaluate the effectiveness of selegiline in treating marijuana dependent individuals. Specifically, this study will determine whether selegiline reduces marijuana craving and withdrawal symptoms, thus leading to reduction or abstinence in marijuana use.

Participants in this 9-week, double-blind, placebo-controlled study will be randomly assigned to receive either selegiline (10 mg/day in two 5 mg pills) or placebo. Study visits will occur twice each week. At each study visit, participants will complete self-reports and urine toxicology tests. Throughout the study, participants will receive weekly individual counseling. The counseling sessions will last 15 minutes. Reduction in marijuana use as well as the number of weeks of consecutive marijuana abstinence will be evaluated.

Eligibility Criteria:
Inclusion Criteria:

* Meets DSM-IV criteria for current marijuana dependence
* Positive urine toxicology test for marijuana
* Reports current marijuana use
* Weighs at least 100 lbs
* Women of childbearing age will be included provided they agree to use adequate contraception

Exclusion Criteria:

* Meets dependence or abuse criteria for alcohol
* Meets dependence criteria for illicit substances other than marijuana
* Serious medical disorders (such as unstable angina or liver failure), that may make participation in the trial unsafe
* Pregnant
* Currently diagnosed with a psychotic disorder
* Currently suicidal or pose a homicidal risk
* Currently taking over-the-counter (e.g., pseudoephedrine) or prescription (e.g., methylphenidate) sympathomimetic agents, antidepressant agents (e.g., tricyclic antidepressants, serotonin reuptake inhibitors, bupropion, other monoamine oxidase inhibitors), or meperidine (Demerol)
* Unable to understand English
* Known hypersensitivity to selegiline hydrochloride
Determination of Performance Characteristics of the MassPLEX Factor II/V Leiden Test

To establish the overall agreement of the MassPLEX Factor II and Factor V Leiden Genotyping Test with bi-directional DNA sequencing for Factor II and Factor V Leiden.

De-identified banked genomic DNA samples derived from whole blood from subjects with suspected thrombophilia will be collected from one or more clinical sites. Three clinical laboratory sites will analyze the samples with the FII/FVL Test. Bi-directional DNA sequencing will be performed on all samples at an independent core reference laboratory.

Eligibility Criteria:
Inclusion Criteria:

* suspected thrombophilia
* 18 years of age or older

Exclusion Criteria:

* none
Exploratory Study of the Expression of the Serotonergic 5-HT4 Receptor in Parkinson's Disease

The research aim to study in detail the motor, cognitive and affective modifications of Parkinsonian patients (compared to control subjects) at a moderate stage of the disease and to analyze by positron emission tomography (PET) imaging with the specific radioligand \[11C\]SB207145 the expression levels of this 5-HT4 receptor. At the same time, the study will monitor the impact of the 5-HTTLPR polymorphisms of Serotonin Transporter (SERT) and Brain-derived neurotrophic factor (BDNF) Val66Met on the expression of the 5-HT4 receptor in subjects.


Eligibility Criteria:
Inclusion Criteria:

* Man or woman : Age between ≥ 50 and ≤ 85 years old
* For women: postmenopausal
* Affiliated to a social security scheme or similar;
* Having given written consent to participate in the free and informed study.
* Level of study: ≥ 6 years of schooling
* only for healthy volunteer : No history of neurological or psychiatric disease
* Only for patient : Having a clinically established or probable diagnosis of Parkinson's disease according to the criteria defined by the Movement Disorder Society at a Hoehn and Yahr stage ≤ 3 (in on dopa conditions) and a duration of evolution of the disease between 2 and 8 years.
* Only for patient : Having a MoCA (Montreal Cognitive Assessment) ≥ 20/30.

Exclusion Criteria:

* Diagnosis other than Parkinson's disease ( for patient only)
* Treated with specific serotonin inhibitors (SSRIs), specific noradrenaline inhibitors (SNRIs), tricyclic antidepressants, monoamine oxidase inhibitors (MAOIs) and neuroleptics in the last 3 months
* Use of recreational drugs interfering with the serotonergic system (ecstasy, MDMA) or opioids (cannabis, opiates) in the last 3 months or chronic use
* Contraindication to magnetic resonance imaging (MRI) or positron emission tomography (PET)
* Participation in the last year to a study using ionizing radiation or concomitant participation in another research project involving the human being that may interfere with the results or the conclusions of this study
* Exceeding the annual amount of compensation authorized for participation in research protocols
* Deprivation of liberty by judicial or administrative decision, person subject to a legal protection measure
* BMI ≥ 35kg/m2
* Presence of depression (BDI-2 score ≥21), anxiety (Parkinson Anxiety Scale (PAS) score ≥14) or apathy (STARKSTEIN score ≥14) - (for healthy volunteers only)
* Cognitive impairment (MOCA score ≤26) (for healthy volunteers only)
* Current or past neurological or psychiatric pathology (for healthy volunteers only)
* Serious and progressive medical pathology
* Current or past dependence on any addictive substance according to DSM-V (The Diagnostic and Statistical Manual of Mental Disorders) criteria (alcohol, cannabis, hallucinogens, inhalants, opiates, sedatives, stimulants), except tobacco and caffeine. (for healthy volunteers only)
Evaluation of The Stability of Orthodontic Treatment After First Premolar Extraction Using Combined Retention Protocol

The aim of this study is to compare between the stability of anterior and posterior segments in both arches using bonded lingual retainers versus a combined protocol of retention (bonded lingual retainer and vacuum formed retainers). The effect of different treatment changes achieved on the post-treatment stability will be studied in both groups.

Hypothesis: No difference between BR and BR+VFR regarding the stability of anterior segment alignment and posterior segment alignment and interdigitation

Retention is necessary to be done after orthodontic treatment. It aids to prevent the tendency for relapse of teeth toward their pretreatment position. Fixed or removable retention appliances can reduce the risk of relapse, but to date there is still limited evidence on treatment protocols, wearing time and duration. However, long-term retention with bonded lingual retainers is commonly recommended and often considered the gold standard (method of first choice) in orthodontic retention. Regardless of the expected benefits concerning tooth stabilization, aesthetic appearance and independency from the patient's compliance, there have been increasing numbers of reports on undesirable changes in tooth position in the presence of retainers. Since "active" lingual retainers are able to exert forces to teeth, they have been suspected of causing torque changes of adjacent incisors ("X-effect"). Therefore, several authors recommend to insert removable and fixed in both arches for maximum relapse prevention.

Eligibility Criteria:
Inclusion Criteria:

1. Adult patients at the end of comprehensive orthodontic treatment after extraction of upper and lower first premolars and requiring subsequent application of a lingual and palatal bonded retainers
2. Good oral hygiene
3. Patients whom the pre-treatment records (models) are available
4. Good finishing criteria (ABO grading system)

Exclusion Criteria:

1. Non-extraction orthodontic treatment
2. Poor oral hygiene
3. Dental/congenital anomalies ex: Missing laterals, transposed canines, Cleft lip and palate/craniofacial syndromes
4. Poor finishing criteria (ABO grading system)
N-of-1 Trials Using mHealth in Chronic Pain

Chronic musculoskeletal pain is an important problem, and treatments are often prescribed in a "trial and error" fashion. Clinicians prescribe a treatment to a patient and then wait and see if the treatment is successful. If the treatment is unsuccessful, they will try a different treatment. The disadvantage to this method is that it may take a long time to find a successful treatment.

The purpose of the PREEMPT Study is to test whether using a mobile phone application ("Trialist app") that allows patients and their health care providers to run personalized experiments comparing two pain treatments is more effective than usual care. Patients download the app, and working with their clinicians, set up a personalized trial that makes sense for them. Every day they answer questions to track levels of pain and side effects of treatment, such as fatigue and constipation. Once the personalized trial has ended, the responses to these daily questions on each treatment will be compared. During a regular clinic visit, the patient and the clinician will review visual displays of the results to facilitate treatment decision-making. Approximately 250 patients will be enrolled in the study. Half the patients will use the app and review results with the clinician, and half the patients will continue with their regular care (i.e., will not use the app). The two groups will be compared to see if using the app is successful in improving long term pain outcomes. The goal of the intervention using the Trialist app is to help patients engage actively and collaboratively with their clinicians and identify effective treatments more quickly.


Eligibility Criteria:
Inclusion Criteria:

* Chronic musculoskeletal pain (e.g., neck, back, extremities) operationalized as pain present for 6 weeks or more and a pain score of 4 or higher (on a 0-to-10 scale) on at least one of three items from the PEG pain scale
* Age 18-75 years
* Own web-enabled Android or iOS phone with data plan
* In judgment of treating clinician, pain potentially amenable to treatment with acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), low-dose opioids, a complementary/alternative treatment such as massage or meditation, or a simple combination of these treatments
* Ability to speak and read English

Exclusion Criteria:

* Treated with surgery, radiation or chemotherapy for cancer in past 5 years
* Other medical conditions that in clinician's judgment would limit life expectancy to less than 2 years or imperil patient safety
* Pregnant or breastfeeding
* Dementia, bipolar disorder, schizophrenia, active suicidality
* Current alcohol or prescription drug abuse; history of disruptive behavior
* Failed 5 or more analgesic medications because of lack of effectiveness or poor tolerability
Efficacy Study to Evaluate the Effect of New Antiviral Drugs on HCV Infection.

The purpose of this study is to determinate the AMH levels before and after antiviral therapy with Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir in comparison with age-matched HCV-positive women not undergoing antiviral treatment.

The study is interventional, controlled randomized (block 2:1 case: controls) in open label.

Eligibility Criteria:
Inclusion Criteria:

* Female between 18 and 35 years of age at the time of Screening
* Childbearing potential and sexually active with male partner(s) currently using at least one effective method of birth control at the time of screening and two effective methods of birth control while receiving study drugs, starting with Study Day 1 and for 7 months after stopping study drug.
* Females must have negative results for pregnancy tests
* Chronic HCV-infection prior to study enrollment
* Screening laboratory result indicating HCV GT 1b or GT 1a or GT 4 infection.
* Must be able to voluntarily sign and date an informed consent form
* Liver biopsy within 24 months prior to or during screening demonstrating a Metavir score of 2 or less or an Ishak score of 3 or less or Screening FibroScan® result of ≤ 9.6 kPa;

Exclusion Criteria:

* Women who are pregnant or breastfeeding
* Positive test result for HBsAg and HIV Ab
* Recent history of drug or alcohol
* HCV genotype performed during screening indicates more than 1 subtype or co-infection with any other genotype.
* Use of medications contraindicated
* Use of known strong inducers of cytochrome P450 3A (CYP3A) or strong inducers of cytochrome P450 2C8 (CYP2C8) or strong inhibitors of CYP2C8
* History of solid organ transplant.
* Confirmed presence of hepatocellular carcinoma
* Current use of any investigational or commercially available anti-HCV agents
* Screening laboratory analyses showing any of the following abnormal laboratory results
The Availability and Safety Study of Remimazolam Besylate for Injection on Sedation of ERAS Patients

This trial intends to evaluate Remimazolam Besylate's availability and safety compared with propofol.


Eligibility Criteria:
Inclusion criteria

* Meet criteria of enhanced recovery after surgery (ERAS);
* Mechanical ventilated when enrolled and have estimation of more than 10 hours of mechanical ventilation in ICU
* Aged between 18-75 years old AND 18kg/m2 ≤ BMI ≤ 30 kg/m2;
* Clearly know the purpose and objective of this clinical study and voluntarily enrolled.

Criteria of ERAS: (1) without dysfunction of nervous system or Glasgow Coma Score \> 12; (2) a satisfied glucose level (random blood glucose\<11.1mmol/L during screening stage) for diabetes mellitus patients; (3) Without acute coronary syndrome in recent 6 months; (4) Without bradycardia and third-degree atrioventricular block (except for patients with pacemaker) during screening stage; (5) systolic blood pressure\>90mmHg with no usage of vasoactive agent during screening stage; (6) without mental illness (schizophrenia, depressive disorder), cognitive dysfunction (identified by MMSE), epilepsy, history of abuse of psychotropic or anesthesia medication; (7) without disorder of coagulation function (PT/INR/APTT \> 1.5×upper limit), bleeding tendency (active peptic ulcer), under treatment of thrombolysis and anticoagulant; (8) without disorder of liver function (ALT/AST \> 2×upper limit and total bilirubin\>1.5×upper limit); (9) without disorder of renal function (Creatine or BUN/Urea\>1.5×upper limit); without dialysis patients.

Exclusion criteria

* Allergy to component of Remimazolam besylate for injection;
* Woman in gestation and lactation period;
* Enrolled in other clinical trails in recent 3 months;
* Other circumstance that identified by researchers that do not suitable for this clinical trial.
Identifying Atopic Dermatitis Patients at Risk for Developing Conjunctivitis During Dupilumab Treatment

Study on ophthalmological comorbidities and the underlying pathomechanisms of conjunctivitis during dupilumab treatment in atopic dermatitis (AD) patients. Patients participate in the Bioday Registry.


Eligibility Criteria:
Inclusion Criteria:

* Adult patients with atopic dermatitis indicated for dupilumab, without current use of oral immunosuppressive treatment .

Exclusion Criteria:

* Treatment with oral or ocular immunosuppressive drugs 2 weeks prior to start of dupilumab treatment